To address this question, we established a Villin-driven Brca2 conditional knockout mouse to monitor gastrointestinal tumor formation, with or without the application of N-methyl-N-nitrosourea treatment or Trp53 deletion. This evidence concerns the gene BRCA2 and digestive system neoplasm.